Abbott Laboratories
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
IE
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Abbott Laboratories (ABT) Business News
Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more
-
CalendarDateSuMoTuWeThFrSaSelected FilterNo selection
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings
Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
ABT Fairly Valued by DCF at $86
Capital & Planning LLC Has $2.33 Million Position in Abbott Laboratories $ABT
Carnegie Investment Counsel Grows Stock Holdings in Abbott Laboratories $ABT
ABT Fairly Valued by DCF at $86
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth
Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
CCLA Investment Management Cuts Stock Holdings in Abbott Laboratories $ABT
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings
6:07 AM | Tuesday | Apr 14, 2026
Abbott Laboratories (NYSE: ABT) will release earnings for its first quarter before the opening bell on Thursday, April 16.
Read full article
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings
BenzingaAbbott Laboratories (NYSE: ABT) will release earnings for its first quarter before the opening bell on Thursday, April 16.
Read full article
Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Zacks Investment ResearchBesides Wall Street's top-and-bottom-line estimates for Abbott (ABT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Read full article
ABT Fairly Valued by DCF at $86
GuruFocusOn April 13, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT). The stock has seen a challenging performance recently, with a year-to-date decl
Read full article
Capital & Planning LLC Has $2.33 Million Position in Abbott Laboratories $ABT
Defense WorldCapital and Planning LLC increased its position in Abbott Laboratories (NYSE: ABT) by 135.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,758 shares of the healthcare product maker's stock after buying an additional 10,780 shares during the period. Capital and Planning LLC's
Read full article
Carnegie Investment Counsel Grows Stock Holdings in Abbott Laboratories $ABT
Defense WorldCarnegie Investment Counsel increased its stake in shares of Abbott Laboratories (NYSE: ABT) by 3.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 318,798 shares of the healthcare product maker's stock after purchasing an additional 9,703 shares during the period. Abbott Laboratories
Read full article
ABT Fairly Valued by DCF at $86
GuruFocusOn April 10, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company currently facing a challenging price performance with a year-to-date
Read full article
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth
Zacks Investment ResearchAbbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential
Seeking AlphaAbbott Laboratories has declined over 16% since my last review, which was previously rated a HOLD, as the valuation was a little rich. The acquisition of Exact Sciences adds a solid piece to a company with a long, proven track record. The segments were kind of a mixed bag in the most recent earnings report, and I'll be monitoring the struggling areas to see where they might go.
Read full article
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
PRNewsWireWith chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.
Read full article
CCLA Investment Management Cuts Stock Holdings in Abbott Laboratories $ABT
Defense WorldCCLA Investment Management decreased its holdings in Abbott Laboratories (NYSE: ABT) by 10.0% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 845,716 shares of the healthcare product maker's stock after selling 94,471 shares during the quarter. CCLA Investment Management's holdings in Abbott
Read full article